Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Sees Large Increase in Short Interest

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 27,309 shares, an increase of 23.3% from the December 15th total of 22,155 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average trading volume of 8,216 shares, the days-to-cover ratio is presently 3.3 days. Based on an average trading volume of 8,216 shares, the days-to-cover ratio is presently 3.3 days. Approximately 0.9% of the company’s stock are sold short.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Several hedge funds and other institutional investors have recently modified their holdings of PBE. Royal Bank of Canada grew its position in shares of Invesco Biotechnology & Genome ETF by 22.3% in the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after acquiring an additional 13,767 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Invesco Biotechnology & Genome ETF by 5.9% during the first quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock valued at $2,389,000 after buying an additional 2,103 shares during the last quarter. Signet Financial Management LLC raised its stake in Invesco Biotechnology & Genome ETF by 3.9% during the 2nd quarter. Signet Financial Management LLC now owns 4,351 shares of the company’s stock valued at $279,000 after acquiring an additional 164 shares in the last quarter. Massachusetts Wealth Management lifted its holdings in Invesco Biotechnology & Genome ETF by 1.0% in the second quarter. Massachusetts Wealth Management now owns 18,394 shares of the company’s stock worth $1,179,000 after purchasing an additional 190 shares during the period. Finally, RFG Advisory LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth approximately $300,000.

Invesco Biotechnology & Genome ETF Trading Down 1.3%

PBE opened at $80.91 on Tuesday. The company has a fifty day simple moving average of $81.48 and a 200 day simple moving average of $73.64. The firm has a market cap of $258.10 million, a price-to-earnings ratio of 20.44 and a beta of 0.79. Invesco Biotechnology & Genome ETF has a twelve month low of $54.52 and a twelve month high of $85.73.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.